Amrutanjan Health Care Limited (AMRUTANJAN.NS)
INR 632.05
(-0.61%)
INR 632.05
(-0.61%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.21 Billion INR | 0.0% |
| 2022 | 3.79 Billion INR | -6.39% |
| 2021 | 4.05 Billion INR | 22.29% |
| 2020 | 3.31 Billion INR | 27.17% |
| 2019 | 2.6 Billion INR | 3.47% |
| 2018 | 2.51 Billion INR | 13.49% |
| 2017 | 2.22 Billion INR | -0.0% |
| 2016 | 2.22 Billion INR | 18.9% |
| 2015 | 1.86 Billion INR | 12.11% |
| 2014 | 1.66 Billion INR | 17.53% |
| 2013 | 1.41 Billion INR | 3.71% |
| 2012 | 1.36 Billion INR | -4.53% |
| 2011 | 1.43 Billion INR | 35.81% |
| 2010 | 1.05 Billion INR | 17.42% |
| 2009 | 897.69 Million INR | -0.98% |
| 2008 | 906.6 Million INR | 21.61% |
| 2007 | 745.49 Million INR | 2.99% |
| 2006 | 723.87 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 837.36 Million INR | -16.45% |
| 2023 Q4 | 1 Billion INR | -14.34% |
| 2023 Q1 | 778.63 Million INR | -22.31% |
| 2023 FY | 3.79 Billion INR | 0.0% |
| 2023 Q2 | 993.11 Million INR | 27.55% |
| 2023 Q3 | 1.16 Billion INR | 17.8% |
| 2022 FY | 3.79 Billion INR | -6.39% |
| 2022 Q1 | 709.54 Million INR | -33.16% |
| 2022 Q2 | 1.1 Billion INR | 56.04% |
| 2022 Q3 | 976.45 Million INR | -11.81% |
| 2022 Q4 | 1 Billion INR | 2.63% |
| 2021 Q2 | 1.1 Billion INR | 41.13% |
| 2021 FY | 4.05 Billion INR | 22.29% |
| 2021 Q3 | 1.1 Billion INR | 0.28% |
| 2021 Q4 | 1.06 Billion INR | -4.1% |
| 2021 Q1 | 782.11 Million INR | -15.65% |
| 2020 FY | 3.31 Billion INR | 27.17% |
| 2020 Q1 | 466.18 Million INR | -20.39% |
| 2020 Q3 | 1 Billion INR | 8.67% |
| 2020 Q2 | 921.11 Million INR | 97.59% |
| 2020 Q4 | 927.21 Million INR | -7.37% |
| 2019 Q3 | 827.54 Million INR | 10.62% |
| 2019 Q4 | 585.59 Million INR | -29.24% |
| 2019 Q1 | 445.95 Million INR | -46.83% |
| 2019 Q2 | 748.07 Million INR | 67.75% |
| 2019 FY | 2.6 Billion INR | 3.47% |
| 2018 Q2 | 620.49 Million INR | 73.47% |
| 2018 FY | 2.51 Billion INR | 13.49% |
| 2018 Q4 | 838.81 Million INR | 19.37% |
| 2018 Q3 | 702.69 Million INR | 13.25% |
| 2018 Q1 | 357.68 Million INR | -52.1% |
| 2017 FY | 2.22 Billion INR | -0.0% |
| 2017 Q1 | 316.95 Million INR | -54.43% |
| 2017 Q2 | 563.04 Million INR | 77.64% |
| 2017 Q3 | 629.42 Million INR | 11.79% |
| 2017 Q4 | 746.79 Million INR | 18.65% |
| 2016 Q2 | 555.45 Million INR | 0.0% |
| 2016 FY | 2.22 Billion INR | 18.9% |
| 2016 Q4 | 695.49 Million INR | 17.65% |
| 2016 Q3 | 591.14 Million INR | 6.43% |
| 2015 FY | 1.86 Billion INR | 12.11% |
| 2014 FY | 1.66 Billion INR | 17.53% |
| 2013 FY | 1.41 Billion INR | 3.71% |
| 2012 Q4 | 577.53 Million INR | 60.42% |
| 2012 FY | 1.36 Billion INR | -4.53% |
| 2012 Q2 | 288 Million INR | 104.23% |
| 2012 Q3 | 360.01 Million INR | 25.0% |
| 2012 Q1 | 141.01 Million INR | 0.0% |
| 2011 FY | 1.43 Billion INR | 35.81% |
| 2010 FY | 1.05 Billion INR | 17.42% |
| 2009 FY | 897.69 Million INR | -0.98% |
| 2008 FY | 906.6 Million INR | 21.61% |
| 2007 FY | 745.49 Million INR | 2.99% |
| 2006 FY | 723.87 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 93.108% |
| Hester Biosciences Limited | 3.04 Billion INR | -38.314% |
| Aarti Drugs Limited | 25.28 Billion INR | 83.341% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 76.798% |
| Albert David Limited | 3.62 Billion INR | -16.214% |
| Alembic Limited | 1.57 Billion INR | -167.473% |
| Alkem Laboratories Limited | 126.67 Billion INR | 96.675% |
| Bafna Pharmaceuticals Limited | 1.52 Billion INR | -176.279% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 11.024% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -952.148% |
| Brooks Laboratories Limited | 794.86 Million INR | -429.942% |
| Eris Lifesciences Limited | 20.09 Billion INR | 79.034% |
| FDC Limited | 19.42 Billion INR | 78.32% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 81.551% |
| Gufic Biosciences Limited | 8.06 Billion INR | 47.781% |
| Hikal Limited | 17.84 Billion INR | 76.396% |
| Ind-Swift Limited | 5.02 Billion INR | 16.168% |
| Innova Captab Limited | 10.81 Billion INR | 61.044% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | 80.25% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -101.833% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 93.716% |
| Lincoln Pharmaceuticals Limited | 5.8 Billion INR | 27.443% |
| Lupin Limited | 196.56 Billion INR | 97.857% |
| Mangalam Drugs & Organics Limited | 3.67 Billion INR | -14.666% |
| Medico Remedies Limited | 1.44 Billion INR | -190.663% |
| Morepen Laboratories Limited | 17.01 Billion INR | 75.249% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 74.995% |
| Orchid Pharma Limited | 8.19 Billion INR | 48.591% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 63.411% |
| RPG Life Sciences Limited | 5.82 Billion INR | 27.63% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -172.866% |
| Sigachi Industries Limited | 3.98 Billion INR | -5.583% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 65.986% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 59.934% |
| Themis Medicare Limited | 3.81 Billion INR | -10.339% |
| Unichem Laboratories Limited | 16.57 Billion INR | 74.585% |
| Vaishali Pharma Limited | 862.79 Million INR | -388.215% |
| Wanbury Limited | 5.75 Billion INR | 26.825% |
| Windlas Biotech Limited | 6.3 Billion INR | 33.239% |
| ZIM Laboratories Limited | 3.67 Billion INR | -14.615% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 67.114% |
| Ipca Laboratories Limited | 77.05 Billion INR | 94.534% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.131% |
| Venus Remedies Limited | 5.91 Billion INR | 28.78% |
| Sakar Healthcare Limited | 1.54 Billion INR | -173.229% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 98.548% |
| Divi's Laboratories Limited | 78.45 Billion INR | 94.631% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 67.486% |
| Mankind Pharma Limited | 103.34 Billion INR | 95.924% |
| Sequent Scientific Limited | 13.69 Billion INR | 69.247% |
| Laurus Labs Limited | 50.01 Billion INR | 91.578% |
| Neuland Laboratories Limited | 15.58 Billion INR | 72.973% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | 87.782% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 96.434% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 97.786% |
| Wockhardt Limited | 27.89 Billion INR | 84.897% |
| Bal Pharma Limited | 3.39 Billion INR | -24.176% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 98.491% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 45.312% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | -340.432% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | 74.879% |
| Shilpa Medicare Limited | 11.53 Billion INR | 63.47% |
| Valiant Laboratories Limited | 1.82 Billion INR | -131.373% |
| Ajanta Pharma Limited | 42.08 Billion INR | 89.991% |
| Aarey Drugs & Pharmaceuticals Limited | 3.95 Billion INR | -6.474% |
| Granules India Limited | 45.06 Billion INR | 90.653% |
| Medicamen Biotech Limited | 1.79 Billion INR | -134.922% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -62.484% |
| Piramal Enterprises Limited | 60.33 Billion INR | 93.019% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 96.028% |
| NATCO Pharma Limited | 40.02 Billion INR | 89.475% |
| Suven Life Sciences Limited | 116.92 Million INR | -3502.447% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -735.418% |
| Strides Pharma Science Limited | 40.51 Billion INR | 89.602% |
| Indoco Remedies Limited | 18.17 Billion INR | 76.821% |
| Alpa Laboratories Limited | 1.08 Billion INR | -287.378% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -303.729% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -457.587% |